Equivocal (HER2 IHC 2+) breast carcinomas: gene-protein assay testing reveals association between genetic heterogeneity, individual cell amplification status and potential treatment benefits.

Gyula PekarIonna KasselakiAgnes Pekar-LukacsCsaba DekanyDan HellbergTibor Tot

Published in: Histopathology (2018)

Non-heterogeneous HER2 IHC 2+ tumours tend to be HER2-amplified. Adding the percentage of cells with HER2 >6 copies to the average HER2/CEP17 ratio may facilitate assessment of amplification status in ISH-equivocal cases. The proportion of cells with HER2/CEP17 ≥2.0 contributes information concerning the actual average HER2/CEP17 ratio, depending on tumour type.

Keyphrases

induced apoptosis
cell cycle arrest
single cell
genome wide
copy number
nucleic acid
signaling pathway
gene expression
high throughput
cell therapy
mesenchymal stem cells
dna methylation
cell proliferation
health information
smoking cessation
replacement therapy